How I came to join BI and what is special about it?
My background is a blend of science, engineering and business. After a master in Management Engineering and also in Health Policy, I obtained a PhD in bioinformatics and pharmacogenomics. This specialization allowed me to obtain a view on the biological, informatic and clinical aspects of drug development specifically relating to the impact of genes on drug response. I joined Boehringer Ingelheim 9 years ago as through the Medical Affairs Department at BI US where I was responsible on the West Coast for Flibanserin, a medical treatment for women with hypoactive sexual desire disorder. I was interested in drug development post Phase III and learning about how drugs are launched and supported in the medical community. I became even more interested in the commercial aspects of the pharmaceutical business by working with marketing and sales. Four years later, I joined the Health Economics & Outcomes Research team still representing the West Coast working closely with our key account teams and sales forces supporting launches and formulary access. One of the key wins of my team was Pradaxa, an anticoagulant medication, to be listed on the Kaiser Permanente formulary. I became the head of Making More Health in the US. During this time, I worked with Ashoka, a non-profit organization that promotes social entrepreneurship and the Making More Health US team to drive various initiatives especially around enhancing healthcare access to populations where it is most needed. This project led me to Ingelheim to take on similar market access development projects.